Welcome to our dedicated page for Equillium news (Ticker: EQ), a resource for investors and traders seeking the latest updates and insights on Equillium stock.
Equillium, Inc. (Nasdaq: EQ) is a La Jolla, California–based clinical-stage biotechnology company that publicly describes its focus as developing novel therapies for severe autoimmune and inflammatory disorders. News about Equillium often centers on the progress of its lead candidate EQ504, an investigational aryl hydrocarbon receptor (AhR) modulator, and on corporate actions that support its development strategy.
Readers of this EQ news page can follow company announcements on clinical and preclinical plans for EQ504, including preparations for Phase 1 studies in ulcerative colitis and related gastrointestinal conditions, as well as potential applications in inflammatory lung or pulmonary diseases. Equillium’s press releases also highlight scientific and translational updates, such as key opinion leader events discussing AhR modulation, intestinal inflammation and the unmet medical need in ulcerative colitis.
In addition to pipeline news, Equillium regularly reports on financing transactions like private placements and at-the-market offerings, which it links to funding the development of EQ504 and extending its operating runway. Corporate governance and leadership updates, including changes in board composition, committee membership and senior roles, are disclosed through both SEC filings and news releases.
Another recurring topic in Equillium’s news flow is its cryptocurrency treasury reserve strategy, which the company has described as part of its broader financial and growth objectives. Updates in this area appear alongside information on cash resources, investment policy changes and strategic priorities.
Investors and observers can use this news feed to monitor Equillium’s clinical plans, scientific positioning around AhR modulation, capital-raising activities, Nasdaq listing developments and treasury strategy, all of which shape the company’s path as a clinical-stage biotech focused on immuno-inflammatory diseases.
Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology firm, announced its participation in the Stifel Healthcare Conference and the Jefferies London Healthcare Conference. Company management will present an overview of their clinical assets and discuss upcoming milestones. The Stifel conference is set for November 15 at Lotte New York Place Hotel, while the Jefferies conference will occur on November 17 in London. Webcast access will be available on their website, with archived replays for 90 days.
Equillium presented data on its novel Multi-Cytokine Inhibitor EQ101 for treating alopecia areata at the 6th Annual Dermatology Drug Development Summit. The presentation, made by Dr. Stephen Connelly, highlighted EQ101's selective targeting of IL-2, IL-9, and IL-15 with a favorable safety profile. A Phase 2 study is set to initiate in Q4 2022, aiming to evaluate its efficacy compared to other treatments. EQ101 demonstrated superior hair regrowth compared to ruxolitinib and has previously shown promise in cutaneous T cell lymphoma.
Equillium, Inc. (Nasdaq: EQ) announced the initiation of a Phase 1 study for its investigational drug EQ102, targeting celiac disease. The study involves up to 64 healthy volunteers and aims to evaluate safety and tolerability after administering single and multiple ascending doses. EQ102 is designed to inhibit cytokines IL-15 and IL-21, which are implicated in gastrointestinal inflammation. The CEO highlighted this as a significant milestone, with initial clinical data expected next year. Celiac disease has over 50 million global incidences and currently lacks effective treatments.
Equillium, Inc. (Nasdaq: EQ) presented promising data on its multi-cytokine inhibitors, EQ101 and EQ102, at the La Jolla Immunology Conference. The research indicates that these inhibitors effectively reduce the activity of cytotoxic T lymphocytes and natural killer cells, which are pivotal in autoimmune diseases.
EQ101 and EQ102 demonstrated approximately 50% and 40% reductions in CD4 and CD8 T cell proliferation, respectively. The company plans to initiate a Phase 2 study for EQ101 in alopecia areata and a Phase 1 study for EQ102 in healthy volunteers by year-end 2022.
Equillium announced interim results from the EQUALISE study evaluating itolizumab in lupus nephritis patients. Of the 6 subjects evaluated, 83% achieved a complete or partial response, and 67% attained over 80% reduction in urine protein creatinine ratio (UPCR) by week 28. The treatment showed a favorable safety profile with no serious adverse events. The mean baseline UPCR was notably high at 5.8 g/g, and the study's results point to potential as a competitive therapy in a field where other treatments have fallen short.
Equillium, Inc. (Nasdaq: EQ) announces the acceptance of its abstract for presentation at ACR Convergence, the American College of Rheumatology’s annual meeting, set for November 10-14, 2022. The abstract, titled 'Urine ALCAM is a Strong Predictor of Lupus Nephritis', highlights urinary soluble ALCAM as a potential biomarker for disease severity in lupus nephritis. Equillium develops novel therapeutics targeting autoimmune disorders, including itolizumab, currently undergoing clinical trials for conditions like lupus nephritis and acute graft-versus-host disease.
Equillium will acquire Metacrine in an all-stock merger, strengthening its financial position with an additional
Equillium, a clinical-stage biotechnology company, announces participation in the Wells Fargo Healthcare Conference on September 7 and the H.C. Wainwright Annual Global Investment Conference on September 12. The company will provide insights into its clinical assets and upcoming milestones.
The Wells Fargo event will take place at Encore Boston Harbor at 1:20 PM PT, while the H.C. Wainwright event will be held at Lotte New York Palace Hotel at 12:00 PM PT. Webcast access will be available on Equillium's website.
Equillium, Inc. (Nasdaq: EQ) reported its Q2 2022 financial results, highlighting a net loss of $14.1 million, or $(0.41) per share, compared to a loss of $9.2 million in Q2 2021. R&D expenses rose to $9.5 million, up from $6.0 million, due to increased clinical development costs. G&A expenses also increased to $4.1 million from $2.9 million. The company is advancing its clinical studies, including initiating Phase 2 trials for EQ101 and EQ102 in alopecia areata and celiac disease, respectively. Cash reserves stood at $57.6 million, sufficient to support operations for at least 12 months.
Equillium, Inc. (Nasdaq: EQ) announced a presentation at the 3rd Annual Cytokine-Based Drug Development Summit, showcasing its multi-cytokine inhibitor technology. Dr. Stephen Connelly presented data on EQ101, a tri-specific cytokine inhibitor targeting IL-2, IL-9, and IL-15, which has shown promise in treating inflammatory and neoplastic skin diseases. The company plans to initiate Phase 2 and Phase 1 studies for EQ101 and EQ102, respectively, by year's end. This innovative approach may allow for more selective targeting of cytokines compared to traditional JAK inhibitors.